Cardiorenal Protection in Diabetic Kidney Disease

Cardiorenal Protection in Diabetic Kidney Disease

Over the last 5 years there have been many new developments in the management of diabetic kidney disease. Glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter-2 (SGLT2) inhibitors were initially used for glycemic control, but more recent studies have now shown that t...

Full description

Bibliographic Details
Main Authors:	Jason F. Lee, Ecaterina Berzan, Vikas S. Sridhar, Ayodele Odutayo, David Z.I. Cherney
Format:	Article
Language:	English
Published:	Academya Publishing Co. 2021-04-01
Series:	Endocrinology and Metabolism
Subjects:	diabetes mellitus type 2 diabetic nephropathies heart failure cardiovascular diseases glucagon-like peptide-1 receptor mineralocorticoid receptor antagonists sodium-glucose transporter 2 inhibitors renal insufficiency chronic
Online Access:	http://www.e-enm.org/upload/pdf/enm-2021-987.pdf

Similar Items

Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study
by: Moa Lugner, et al.
Published: (2021-03-01)

Glucagon receptor antagonism induces increased cholesterol absorption[S]
by: Hong-Ping Guan, et al.
Published: (2015-11-01)

Common Drug Pipelines for the Treatment of Diabetic Nephropathy and Hepatopathy: Can We Kill Two Birds with One Stone?
by: Yoshio Sumida, et al.
Published: (2020-07-01)

Long‐term safety and efficacy of the sodium–glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon‐like peptide‐1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52‐week open‐label, multicenter, post‐marketing clinical study
by: Yasuo Terauchi, et al.
Published: (2019-11-01)

Mineralocorticoid Receptor Antagonists—Use in Chronic Kidney Disease
by: Wiktoria Baran, et al.
Published: (2021-09-01)

How Do the Recent Major Randomized Controlled Trials Inform Best Use of the Novel Glucose-Lowering Agents?
by: Louisa Sukkar, et al.
Published: (2020-12-01)

Cardiovascular Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Older Patients in Routine Clinical Care With or Without History of Atherosclerotic Cardiovascular Diseases or Heart Failure
by: Buse, J., et al.
Published: (2022)

Neutral Effects of Combined Treatment With GLP-1R Agonist Exenatide and MR Antagonist Potassium Canrenoate on Cardiac Function in Porcine and Murine Chronic Heart Failure Models
by: Evelyne J. Demkes, et al.
Published: (2021-07-01)

Pasireotide‐induced hyperglycemia in a patient with Cushing's disease: Potential use of sodium‐glucose cotransporter 2 inhibitor and glucagon‐like peptide‐1 receptor agonist for treatment
by: Masato Shikata, et al.
Published: (2020-12-01)

Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study
by: Su Jin Jeong, et al.
Published: (2021-05-01)

New Potential Targets of Glucagon-Like Peptide 1 Receptor Agonists in Pancreatic β-Cells and Hepatocytes
by: Won-Young Lee
Published: (2017-02-01)

Secretion of incretin hormones in people having risk factors for type 2 diabetes mellitus
by: E A Shestakova, et al.
Published: (2014-10-01)

Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes
by: Gagik R. Galstyan, et al.
Published: (2017-10-01)

Dulaglutide‐combined basal plus correction insulin therapy contributes to ideal glycemic control in non‐critical hospitalized patients
by: Nobutoshi Fushimi, et al.
Published: (2020-01-01)

Empagliflozin and Liraglutide Differentially Modulate Cardiac Metabolism in Diabetic Cardiomyopathy in Rats
by: Nguyen Ngoc Trang, et al.
Published: (2021-01-01)

Increased Body Weight and Fat Mass After Subchronic GIP Receptor Antagonist, but Not GLP-2 Receptor Antagonist, Administration in Rats
by: Sara Baldassano, et al.
Published: (2019-08-01)

Achieving postprandial glucose control with lixisenatide improves glycemic control in patients with type 2 diabetes on basal insulin: a post-hoc analysis of pooled data
by: Jaime A. Davidson, et al.
Published: (2020-01-01)

Predictors of effectiveness of glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes and obesity
by: Ekaterina V. Tikhonenko, et al.
Published: (2019-03-01)

The associations of incretin hormone concentration with gestational diabetes mellitus
by: Tatiana V. Saprina, et al.
Published: (2016-04-01)

GLP-1 Receptor Agonists and Kidney Protection
by: Eulalia Valentina Greco, et al.
Published: (2019-05-01)

Efficacy and safety of once‐weekly exenatide after switching from twice‐daily exenatide in patients with type 2 diabetes
by: Yuusuke Watanabe, et al.
Published: (2020-03-01)

Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis
by: Elvira D’Andrea, et al.
Published: (2020-09-01)

The Effects of Hypoglycemic Agents on Non-alcoholic Fatty Liver Disease: Focused on Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
by: Chan-Hee Jung, et al.
Published: (2019-03-01)

Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and future
by: Sanjay Kalra, et al.
Published: (2016-01-01)

Astragalus polysaccharide alleviates type 2 diabetic rats by reversing the glucose transporters and sweet taste receptors/GLP-1/GLP-1 receptor signaling pathways in the intestine-pancreatic axis
by: Ze-Min Yang, et al.
Published: (2021-01-01)

Impact of peroxisome proliferator-activated receptor-α on diabetic cardiomyopathy
by: Lin Wang, et al.
Published: (2021-01-01)

Combination Therapy With Semaglutide and Dapagliflozin as an Effective Approach for the Management of Type A Insulin Resistance Syndrome: A Case Report
by: Damas-Fuentes, M., et al.
Published: (2022)

Study of the serum level of fasting glucagon-like peptide-1 in type 2 diabetics and its relation to the glycemic profile
by: Mohamed A Korani, et al.
Published: (2018-01-01)

The Impact of Glucagon-Like Peptide 1 Receptor Agonists on Bone Metabolism and Its Possible Mechanisms in Osteoporosis Treatment
by: Baocheng Xie, et al.
Published: (2021-06-01)

Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes
by: Angelo Maria Patti, et al.
Published: (2020-03-01)

Clinical application of glucagon-like peptide-1 receptor agonists in cardiovascular disease: lessons from recent clinical cardiovascular outcomes trials
by: Atsushi Tanaka, et al.
Published: (2018-06-01)

Risk of any hypoglycaemia with newer antihyperglycaemic agents in patients with type 2 diabetes: A systematic review and meta‐analysis
by: Sanaz Kamalinia, et al.
Published: (2020-01-01)

Mineralocorticoid Receptor May Regulate Glucose Homeostasis through the Induction of Interleukin-6 and Glucagon-Like peptide-1 in Pancreatic Islets
by: Rieko Goto, et al.
Published: (2019-05-01)

Adherence to antihyperglycemic medications and glucagon-like peptide 1-receptor agonists in type 2 diabetes: clinical consequences and strategies for improvement
by: Giorgino F, et al.
Published: (2018-05-01)

Editorial: Reviews and Novel Clinical Perspectives on Semaglutide: A GLP-1 Receptor Agonist With Both Injectable and Oral Formulations
by: Juris J. Meier, et al.
Published: (2021-09-01)

Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6
by: Michael A. Nauck, et al.
Published: (2021-03-01)

Uptake of new antidiabetic medicines in 11 European countries
by: Nika Mardetko, et al.
Published: (2021-06-01)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
by: Nina Vodošek Hojs, et al.
Published: (2021-06-01)

Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis
by: Yoshio Sumida, et al.
Published: (2020-03-01)

A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans
by: Jack Alistair Sargeant, et al.
Published: (2019-09-01)